IDEAYA Biosciences(IDYA) - 2024 Q1 - Quarterly Results

Exhibit 99.1 IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update • ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024 South San Francisco, CA, May 7, 2024– IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and developm ...